Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00306176

Enrollment

100

Registered

2006-03-23

Start date

2005-01-31

Completion date

2006-10-31

Last updated

2007-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus

Keywords

rosiglitazone,exercise,cardiovascular risk factors

Brief summary

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Interventions

DRUGRosiglitazone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Type II diabetes mellitus * Poor glycemic control

Exclusion criteria

* Heart failure * Renal disease * Liver disease * Cardiovascular event

Design outcomes

Primary

Measure	Time frame
Cardiovascular risk factors alterations	—

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026